Your browser doesn't support javascript.
loading
Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies.
Elfaituri, Muhammed Khaled; Ghozy, Sherief; Ebied, Amr; Morra, Mostafa Ebraheem; Hassan, Osama Gamal; Alhusseiny, Ahmed; Abbas, Alzhraa Salah; Sherif, Nourin Ali; Fernandes, Juliano Lara; Huy, Nguyen Tien.
Afiliación
  • Elfaituri MK; Faculty of Medicine, University of Tripoli, Tripoli, Libya.
  • Ghozy S; Online Research Club, Nagasaki, Japan.
  • Ebied A; Online Research Club, Nagasaki, Japan.
  • Morra ME; Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Hassan OG; Neurosurgery Department, El Sheikh Zayed Specialized Hospital, Giza, Egypt.
  • Alhusseiny A; Online Research Club, Nagasaki, Japan.
  • Abbas AS; Egyptian National Blood Transfusion Services, Alexandria, Egypt.
  • Sherif NA; Online Research Club, Nagasaki, Japan.
  • Fernandes JL; Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Huy NT; Online Research Club, Nagasaki, Japan.
Vox Sang ; 116(8): 887-897, 2021 Sep.
Article en En | MEDLINE | ID: mdl-33634883
BACKGROUND AND OBJECTIVES: Iron overload in thalassaemia is a crucial prognostic factor and a major cause of death due to heart failure or arrhythmia. Therefore, previous research has recommended amlodipine as an auxiliary treatment to current chelating agents for reducing iron overload in thalassaemia patients. MATERIALS AND METHODS: A systematic review and meta-analysis of the results of three randomized clinical trials evaluating the use of amlodipine in thalassaemia patients through 12 databases were carried out. RESULTS: Our final cohort included 130 patients. Insignificant difference in decreasing liver iron concentrations was found between amlodipine and control groups {weighted mean difference = -0·2, [95% confidence interval = (-0·55-0·15), P = 0·26]}. As regards serum ferritin, our analysis also showed no significant difference in serum ferritin between amlodipine and control groups {weighted mean difference [95% confidence interval = -0·16 (-0·51-0·19), P = 0·36]}. Similarly, there was insignificant difference in cardiac T2* between amlodipine and control groups {weighted mean difference [95% confidence interval = 0·34 (-0·01-0·69), P = 0·06]}. CONCLUSIONS: Despite the growing evidence supporting the role of amlodipine in reducing iron overload in thalassaemia patients, our meta-analysis did not find that evidence collectively significant. The results of our simulation suggest that when more data are available, a meta-analysis with more randomized clinical trials could provide more conclusive insights.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talasemia / Talasemia beta / Sobrecarga de Hierro Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Vox Sang Año: 2021 Tipo del documento: Article País de afiliación: Libia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talasemia / Talasemia beta / Sobrecarga de Hierro Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Vox Sang Año: 2021 Tipo del documento: Article País de afiliación: Libia Pais de publicación: Reino Unido